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Co-prescription of antiepileptic drugs and contraceptives☆
Hao Wang⁎, Jens H.J. Bos, Lolkje T.W. de Jong-van den Berg
Department of Pharmacoepidemiology and Pharmacoeconomics, Division of Pharmacy, University of Groningen, 9713 AV Groningen, the Netherlands
Received 20 December 2010; revised 27 April 2011; accepted 27 April 2011Abstract
Background: Enzyme-inducing antiepileptic drugs (AEDs) reduce the efficacy of oral contraceptives. Little is known of contraceptive
practice among reproductive-age women who receive AEDs.
Study Design: We explored the use of contraceptive methods among Dutch women aged 15 to 49 years with prescriptions of AEDs using
pharmacy dispensing database. Drug dispensing data of AEDs and contraceptives in 2006 was retrieved from the InterAction Database
(IADB.nl database). The prevalence of contraceptives use and distribution of different contraceptive methods were calculated.
Results: Of women who used enzyme-inducing AEDs in combination with any highly effective contraceptive method, over 40% were on an
oral contraceptive (OC) containing b50 mcg estrogen. IUDs and injectable contraception were used in 22.5% of women receiving AEDs in
combination with any highly effective contraceptive method, and 33.2% in those receiving enzyme-inducing AEDs in combination with any
highly effective contraceptive method.
Conclusion: Fertile-age women who received AEDs often relied on less effective contraceptive methods. Prescribers should be more aware
of the interaction between AEDs and OCs.
© 2012 Elsevier Inc. All rights reserved.Keywords: Antiepileptic drug; Enzyme inducing; Contraceptive; Women1. Introduction
Epilepsy affects 0.5-1.0% of the population. About half of
these are women, many of childbearing age. Co-administra-
tion of oral contraceptives (OCs) and antiepileptic drugs
(AEDs) is a common clinical situation which calls for
specific considerations of possible drugs interactions. Some
AEDs, i.e., the enzyme-inducing AEDs, induce cytochrome
P450 hepatic enzyme activity which increases the rate of
metabolism of both estrogen and progestrogens, and thus
lower the blood levels of these hormones [1]. The main
consequences of these interactions are increased risk of
unintended pregnancy. Given the increasing evidence of the
teratogenic effects of some AEDs [2], contraceptive efficacy
is of greater concern for women treated with AEDs than for
women in the general population. The usual OC containing
b50 mcg of estrogen is susceptible to a lower hormonal
effect by AED interaction, resulting in contraceptive failure.☆ There was no funding for this study.
⁎ Corresponding author. Tel.: +31 50 3632476; fax: +31 50 3632772.
E-mail address: hao.wang@med.umcg.nl (H. Wang).
0010-7824/$ – see front matter © 2012 Elsevier Inc. All rights reserved.
doi:10.1016/j.contraception.2011.04.017Epileptic women treated with enzyme-inducing AEDs
should be advised to use an OC containing at least 50 mcg
of estrogens [3]. There is little published information on
contraceptive prescribing patterns for women of childbearing
age who use AEDs. A UK study using the general practice
research database reported that 56% of epileptic women
using both enzyme-inducing AED and an OC, took a low
dose estrogen OC [4]. However, only OCs were included in
this study. The present study explored the choice of highly
effective contraceptive methods, including intrauterine
device (IUD) and injectable contraception among Dutch
women who were prescribed an AED, compared with
women in the general population.2. Methods and materials
This study was performed using the InterAction Database
(IADB.nl database) (http://www.IADB.nl), a longitudinal
pharmacy dispensing database in the northern Netherlands
with detailed patient-based drug prescription information.
The procedures and sources of data have been documented
[5,6]. Briefly, the IADB.nl database comprises all pharmacy
Table 1





Name ATC-code Name ATC-code
phenobarbital N03AA02 ethosuximide N03AD01
primidone N03AA03 clonazepam N03AE01
phenytoin N03AB02 valproic acid N03AG01
carbamazepine N03AF01 vigabatrin N03AG04
oxcarbazipne N03AF02 gabapentin N03AX12
felbamate N03AX10 levetiracetam N03AX14
topiramate N03AX11 pregabalin N03AX16
lamotrigine N03AX09
ATC-code: Anatomical Therapeutic Chemical code.
29H. Wang et al. / Contraception 85 (2012) 28–31prescriptions from approximately 500,000 persons during
1998-2007 and is considered representative of the Dutch
population in terms of drug use. Commitment of people to
their pharmacy has been shown to be high in the
Netherlands, ensuring complete medication histories of
individuals [5]. Each record has information on the name
of the drug, the date of dispensing, the amount dispensed, the
dose regimen and the prescribing physician. The indication
for each prescription is not registered. All drugs are coded
according to the Anatomical Therapeutic Chemical (ATC)
classification system (WHO). The database does not include
information on over-the counter medication and medication
dispensed during hospitalization.
We selected from the IADB women aged 15 to 49 years
with at least one prescription of AED (ATC code N03⁎) in
2006. AEDs were grouped into enzyme-inducing AEDs
and non-enzyme-inducing AEDs as shown in Table 1.
Lamotrigine has no significant effect on ethinylestradiol
concentrations, but we labeled it as enzyme-inducing AED
because it reduces the levonorgestrel level [7]. We also
selected women from the IADB who had at least one
prescription of a contraceptive (ATC G02B⁎, G03A⁎,
G03HB01) in 2006. Selection of contraceptives was on theTable 2






Prevalence of any highly effective contraception 223 30.1 336
Distribution of contraceptive methods
OC, contents =50 mcg estrogen 34 15.2 31
OC, contents b50 mcg estrogen 97 43.5 235
Intrauterine device (IUD) 19 8.5 6
Injectable contraception 55 24.7 46
Combinedb 18 8.1 18
EI-AED: enzyme-inducing antiepileptic drug.
p1: compared with EI-AED users; p2: compared with non-EI-AED users.
a Exclude AED-users.
b Using more than one highly effective contraceptive method.basis of HPK-codes (trade product codes) to distinguish
different quantities of substances from contraceptives
containing the same substances. Contraceptives were
grouped into OCs containing estrogen 50 mcg, OCs
containing estrogen lower than 50 mcg, IUDs and
injectable contraceptives. We calculated the prevalence of
contraceptives use and distribution of different contracep-
tive methods among enzyme-inducing AED users, non-
enzyme-inducing AED users and women without AEDs.
Analyses of differences in proportions were carried out
using SPSS version 16.0. All p values were two-tailed and
considered significant at pb.05.
This paper is approved by IADB.nl advisory board.3. Results
From the IADB.nl database, we identified 1,630 women
aged 15-49 years in the northern Netherlands who had
received at least one prescription of AED in 2006. Of
AED users, 888 (54.5%) used non-enzyme inducing AEDs
and 742 (45.5%) used enzyme inducing AEDs. Of the
AED using women 34.3% were prescribed highly effective
contraceptives compared with 41.2% (57,682/140,012) for
the general population of women aged 15-49 years
(pb.001) (Table 2).
The distribution of different highly effective contracep-
tive methods among the AED-users and the general
population is shown in Table 2. Women using AEDs and
any highly effective contraceptive method more often
received an OC with an estrogen content of 50 mcg
compared to the general population (11.6% vs. 2.1%,
pb.001). The significantly higher proportion of OC with an
estrogen content of 50 mcg was even seen among women
taking non-enzyme-inducing AEDs and using any highly
effective contraceptive method (9.2% vs. 2.1%, pb.001). Of
women who were prescribed any enzyme-inducing AED and







37.8 .001 57682 41.2 b.001 .4
9.2 .2 1230 2.1 b.01 b.01
69.9 b.01 51371 89.1 b.01 b.01
1.8 .01 2873 5 .2 .1
13.7 .04 1703 3 b.01 b.01
5.4 .2 505 0.8 b.01 b.01
30 H. Wang et al. / Contraception 85 (2012) 28–31received a prescription of OC with an estrogen content less
than 50 mcg. The corresponding values were significantly
higher for non-enzyme-inducing AED users and for the
general population. Compared to the general population,
IUDs and injectable contraception were more frequently
prescribed among women who received AEDs (22.5% vs.
7.9%, pb.001), in particular among enzyme-inducing AED
users (33.2% vs. 7.9%, pb.001) (Table 2).4. Discussion
We examined the prescription pattern of contraceptives
co-prescribed with AEDs and showed that of women who
used enzyme-inducing AEDs in combination with any
highly effective contraceptive method, over 40% were on a
low estrogen content OC. Epileptic women were more often
on other contraceptive methods such as IUDs or injectable
contraception compared with the general population.
Our results are similar to an early UK study, which
showed that of epileptic women using both an enzyme-
inducing AED and an OC, more than half took a low dose
estrogen OC [4]. However, there was no information on use
of IUDs or injectable contraception in that study. For women
with epilepsy, planning their pregnancy is important given
the teratogenic effects of some antiepileptic drugs. AEDs are
increasingly being used in therapy for other conditions such
as migraine, bipolar disorder, and pain. Thus, the teratogenic
concerns do not only affect women with epilepsy. Contra-
ception is an integral part of planning a pregnancy, but
knowledge of the interactions between OCs and AEDs is
unsatisfactory. An early survey in the US suggested that
medical practitioners had limited knowledge of interactions
between contraception and AEDs in women with epilepsy
[8]. In another US study, only 4% of neurologists and none
of the obstetricians knew the effects of the six most common
AEDs on OCs [9]. A survey published in 2005 showed that
about 70% of primary care physicians recognized that certain
AEDs might interfere with the efficacy of OCs [10].
Moreover, women with epilepsy were poorly informed on
the potential interaction between AEDs and OCs [11] and
had limited knowledge of this issue [12]. In a cross-sectional
questionnaire study among reproductive-age women with
epilepsy presenting for routine outpatient visits to an urban,
academic medical center, 50% of prior pregnancies were
unplanned [13].
Women using AEDs were more frequently prescribed
long-term contraceptive methods compared to general
population, such as the IUDs which do not depend on
hormonal changes for their contraceptive activity. These
differences in prescribing patterns indicate that a number of
physicians are aware that contraception in women on AED's
should be optimally effective. Our study also indicated that
women on non-enzyme-inducing AEDs were more frequent-
ly prescribed an OC with 50 mcg estrogen, which might not
be necessary and predispose to increased thrombo-embolicrisk. It is possible that prescribers were not aware which
AEDs are enzyme inducers and which are not. In our study,
highly effective contraceptive use among women using
AEDs was lower than in the general population. It is
consistent with a UK study which reported that 16.7% of the
epileptic women were on an OC compared with 25% in the
general population [4]. A limitation of our study is that there
was no outcome data that could allow us to determine the
differences of contraceptive failure between the women on
enzyme-inducing AEDs and non-enzyme-inducing AEDs.
In summary, our study showed that many fertile age
women using AEDs were not prescribed the correct dose of
an oral contraceptive. Women who are on enzyme-inducing
AEDs should not be prescribed low dose estrogen oral
contraceptives. The hazard of contraceptive failure and
unwanted pregnancy is greatly avoidable. Our results
highlight the need for better education of prescribers
regarding the interaction between AEDs and OCs, while
pharmacists should play an active role.Acknowledgments
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